Home >   Products   >  Advanced Search

5-Methylpyrazine-2-carboxylic Acid 4-Oxide
(CAS RN:51037-30-0 Product Number:M2053)


5-Methylpyrazine-2-carboxylic Acid 4-Oxide
Synonym Acipimox
Synonym 2-Carboxy-5-methylpyrazine 4-Oxide
Synonym 5-Carboxy-2-methylpyrazine 1-Oxide

General Information

Product Number M2053

* Items available from stock in Japan will be delivered in 1-2 weeks.
* Please contact us if you need further information.
(Sales Dept Tel: 800-423-8616 / 503-283-1681 E-mail: Sales-US@TCIchemicals.com)
* To send your quote request for bulk quantities, please click on the “Request Bulk Quotation” button. Please note that we cannot offer bulk quantities for some products.
* TCI frequently reviews storage conditions to optimize them. Please note that the latest information on the storage temperature for the products is described on our website.

Purity/Analysis Method >98.0%(GC)
Storage Temperature 0-10°C
M.F. / M.W. C6H6N2O3=154.13
CAS RN 51037-30-0
Related CAS RN
MDL Number MFCD00865757
  • Product Details
  • Safety & Regulations
  • Reference & Application


Appearance White to Almost white powder to crystal
Purity(GC) min. 98.0 %

Data of Reference

mp 180°C(lit.)


Beilstein 25(5)4,200
Reaxys-RN 777471
PubChem SID 135726995
Merck Index(14) 111
RTECS# UQ2453000


Signal Word Warning
Hazard Statements
  • H319
  • :Causes serious eye irritation.
Precautionary Statements
  • P264
  • :Wash hands and face thoroughly after handling.
  • P280
  • :Wear eye protection.
  • P305+P351+P338+P337+P313
  • :If in eyes: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continue rinsing. If eye irritation persists: Get medical advice or attention.

Transport Information

HS Number 2933.99.8290


Acipimox: A Long-Acting Antilipemic Agent

Acipimox, a nicotic acid [N0082] analogue, is a long-acting antilipemic agent. It inhibits the release of non-esterified fatty acids from adipose tissue and reduces total serum triglyceride and cholesterol levels. These decrease occur in the in the very low density lipoprotein (VLDL) fraction and in the low density lipoprotein (LDL) fraction. In addition, acipimox increases high density lipoprotein (HDL) cholesterol. It is also reported to improve insulin sensitivity in diabetes. It is reported that acipimox acts on the nicotinic acid receptor, inhibiting the enzyme triglyceride lipase. (The product is for research purpose only.)


PubMed Literature

Page Top